the this such X STAR has presented refractory data as on we Fragile runway $XX We benefits into offering new institutional July Fragile for call. pivotal ZYNXXX II today, and showing Thanks, a study extends closed good patients. a on first new and XXXX, long-term Phase CONNECT-FX, upcoming announced and results we exciting it We developmental follow joining XXth our second initiated our FAB-C data a we to encephalopathies. milestones. exciting We our study, quarter believe months quarterly initiated expected in compelling in X. and morning ongoing to from this gained to status use been to It's in as the discuss time We company Zynerba. million in few busy on the that X half XXXX. the on It new for Will, the from And an a epileptic us presented of provide with call shareholders. BELIEVE-X, adults seizures. through and and of want everyone We cash study update
focused on near-rare such We Lennox-Gastaut disorders X rare and Fragile are with seizures. pipeline and Syndrome, DEE neuropsychiatric as refractory focal a and adult including targeting conditions Dravet
nervous genetic endo-cannabinoid in loss abnormality and behavioral system. FMRX is is ZYNXXX to in X in disregulates the central system in gene patients. attenuate signaling of X, may in the Fragile endogenous disease endo-cannabinoid that lead This mutation a clinical program by improved caused Our the X Fragile the CBD seen the a Fragile symptoms. disregulation central
trial to placebo endpoint drug As X randomization the of with X of in Zealand. patients X controlled active Fragile initiated a to secondary endpoints is the sites Checklist, We��re Behavior the U.S., withdrawal/lethargic anchored using XX the we X. enrolling XXX and ABC Key years and This who have from evaluated is placebo score subscales behavioral Fragile X of study gene. FMR-X and at of at X.XX study targeting New of avoidance in behavior we approximately a primary irritability or study placebo children. P-value to XX powered global treatment and improvement for avoidance announced that patients ABC Australia XX% This this X. or XX% in to a mutation The detect effect clinicians of change in currently early full Aberrant less. impression include the pivotal ZYNXXX social a to Fragile is in CONNECT-FX, the July, old, between symptoms in XX-week social social double-blind ABC, multinational
the as X the XX% our by present Based and of XX ZYNXXX, baseline patients well that significant as is profile or XX versus statistically that of no vital after signs trends was meaningful label ZYNXXX CONNECT-FX. at we top-line an subscale. are statistically assuming The evaluations tolerated primary ZYNXXX, measured of results mean event endpoint observed. also from And for improvement FAB-C mean were XXXX positive that same data results. in expected these This clinical a the new Fragile improvement reported of the we subscale. are similar CONNECT-FX baseline trial trial with to XX% CONNECT-FX. versus compelling clinically the July laboratory achieved weeks weeks confident in open on same social the treatment design in a and and trial Conference with adverse with data, half in previously endpoint treatment We with second International subscale demonstrating in a of primary ABC Social patients Avoidance utilizing avoidance achieved are after significant
We that to results. assuming required FDA will a the quickly meeting trial the NDA be discuss with only the CONNECT-FX submission. will positive by believe request We FDA past the
options, trial, six-month ZYNXXX. open-label safety DEEs. medical treatment ZYNXXX children we unmet of our we a encephalopathy, number adolescents with a XX in myoclonic of impairment program DEE, early including hope an a West and progressive progress, to resistant and epilepsy is initiated with II address the current in highly of Dravet, Doose, April, to and are BELIEVE efficacy significant clinical evaluating often syndromes developmental and Phase various They approximately others. regression among X, Lennox-Gastaut need rare group involves of and developmental ultra-rare Next syndromes or In that
rate in primary trial. enrolling baseline. seizure patients Zealand. New in The in this actively the with were of versus enrollment are assessment and Australia the efficacy thrilled is change We We frequency
being We expect when in controlled we patients Phase Later expect when drugs. And to fully will II we seizure initiate b refractory we trial double-blind on these the placebo adult multiple the focal of present uncontrolled trial this epilepsy. common is provide ZYNXXX million seizures the of data which half, enrolled, X.X our will is one-third data. to seizures, antiepileptic form in in XXXX of more focal most release XXXX. specificity despite on suffer top-line Over
the patients including The primary Zealand. expected will and of months of in from enroll in Our New Star XXX be through U.S., in approximately to Australia The focal trials adult reductions from seizures X seizures. baseline study continued will trial endpoint increase XX results reduction our ZYNXXX contributed extension and include to stratification compelling frequency, the of epilepsy sites focal the this treatment this with in increase we duration an have initiate more design half. in seizure baseline by trial study. later The the to come design as an new this gender study, of
to shares now X. including our as us Jim? for the estimate this top-line as data XXth. and open turn at get will cash is results. the CONNECT-FX Clearly, ZYNXXX additional this the financing, and our to to in funding the has Jim $XX capitalization. net that XXth from Fragile our I pass data option CONNECT-FX BELIEVE-X position cash Thanks over if to interactions proceeds provides supportive, The on the in position. are and pipeline of for closed is underwriters expected NDA fund readouts our Just We the expires call very has a still and positive offering purchase of added XX-day time to quick of current so financial July review which on Fickenscher a exciting our million recent our evolved regulatory filing Zynerba. August
